KRYS — Stock Film
STOCK FILMSCENE 1/10KRYS · $347
Stock Expert AI presents
KRYS
Krystal Biotech, Inc
~5 min film100% real numbersplain English
WHAT DOES THIS COMPANY DO?
Krystal Biotech, Inc. What it actually does.

Develops redosable gene therapies for serious rare diseases. Now — the numbers.

on the stock market since 2017
295 employees
$10B market value
Revenue last year:
$389.1M
The net profit left over:
$204.8M
Out of every $100 in sales, $53 stays as net profit.
THE SLICE THAT TURNS INTO PROFIT: 53%

This is an established company with proven profits.

Cash on hand:
$827.8M
Total debt:
$9.3M
The cash outweighs the debt.

If every debt were paid off today, $818.5M would still be left in the vault — a solid cushion for hard times.

THE PRICE TAG
MARKET VALUE / ANNUAL PROFIT
49.9×

The market pays 49.9× for every dollar this company earns in a year — a price that already assumes things go well.

Against companies in its own sector, it looks cheaper than 38% of them.

Analysts' average target sits 11% above today's price.

INSIDE THE REPORT CARD

We compared this company with its own sector across five subjects.

A score of 50 means class average.

BUSINESS QUALITY
96
very strong

Profit power and business quality lead the class.

FINANCIAL STRENGTH
98
very strong

Debt is low and cash is strong; the finances stand solid.

VALUATION
38
weak

Clearly below the class average.

GROWTH
98
very strong

This grade is a blend: the profit side is strong, the sales tempo slow.

PRICE MOMENTUM
87
very strong

The stock has been running stronger than the market lately.

WORTH WATCHING

Valuation: The stock trades at a price that looks expensive next to its earnings; that can cap future returns.

THE FIVE-YEAR JOURNEY
Trading below its recent peak.

The stock trades below its recent peak — about 8% off the top. A pullback, not a collapse.

1
THE BRIGHT SIDE · 1/3
A fat profit margin

The net profit margin is 53% — that slice of every sale is the company’s cushion in hard quarters.

2
THE BRIGHT SIDE · 2/3
Strong cash, light debt

There is $827.8M in the vault; even if every debt were paid off, $818.5M would remain.

3
THE BRIGHT SIDE · 3/3
Delivers on expectations

It met or beat analyst expectations in 7 of the last 8 quarters — consistency is a promise kept.

1
THE RISKS · 1/2
A rich price tag

The company’s market value is 50 times its annual profit. Even a small disappointment could hit the price hard.

2
THE RISKS · 2/2
Executives lean toward selling

Over the last 12 months, executives reported 169 sells against just 23 buys. Not an alarm bell by itself, but a number worth watching.

FINALE · THE GRADE
A+
98 / 100 · MoonshotScore

On our five-subject report card, KRYS sits near the top of the class. A high grade doesn’t mean “guaranteed win” — it means “the evidence looks strong for now.”

The takeaway: KRYS is an established business that has proven its profits for years. The real debate isn’t the quality of the business — it’s whether the price paid for the stock is too high.

The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.

What would you like to do next?
Open the stock page →

Not covered, because the filings we hold do not carry it: the revenue breakdown.

This was a film — not investment advice.
Data: FMP & company filings
Sep 12, 2026 · stockexpertai.com · Stock Film